Montreal, QC May 6, 2003 Biotech company BioAxone Therapeutic has appointed Dr Nigel Brown as chairman of its board of directors. Dr Brown is senior vice-president, business planning, technologies and markets, MDS Pharma Services. Dr Brown holds a PhD in metabolism and a BA in chemistry from the University of Oxford, as well as an MBA from the Open University, England.
“We are very excited to have Dr Brown lead our board,” says Pierre Caouette, BioAxone CEO. “Dr Brown brings expertise in drug development, as well as senior management skills to BioAxone’s board.”
At MDS Dr Brown has responsibility for developing the company’s strategic position, M&A activity, technology assessment and global marketing. Prior to joining MDS Pharma Services, Dr Brown worked for SmithKline Beecham (now GlaxoSmithKline) and The Upjohn Company (now Pfizer). He joined MDS in 1997 as senior director in laboratory operations, and subsequently held increasingly responsible general management positions in drug discovery and development before being promoted into his present role.
BioAxone Therapeutic develops and commercializes technologies that target Rho signaling, which is applicable to medical indications that include central nervous system, cancer and related fields.